James E Dentzer
CIK 1400977 · President & CEO · last filed 2026-07-09
James E Dentzer is a President & CEO who has filed 55 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for CRIS, was dated Jul 9, 2026. Across all open-market trades the lifetime net is −$92.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $58.8K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$58.8K
4
55
-$92.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRIS | President & CEO | 7,436 | $4.83 | $35.9K | -$92.4K | 19 | 2026-07-09 |
| IMNN | Director | 14,963 | $1.53 | $22.9K | $0 | 9 | 2026-05-27 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Chief Financial Officer | — | $38.22 | — | $0 | 1 | 2015-01-13 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Chief Financial Officer | 32,075 | $14.49 | $464.8K | $0 | 26 | 2009-10-01 |
Recent Filings
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-09 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2026-05-27 | IMNN | Grant (A) | +11,148 | $24.5K | EDGAR |
| 2026-03-23 | CRIS | Conv (C) | +133,333 | $0 | EDGAR |
| 2026-03-18 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | IMNN | Grant (A) | — | $0 | EDGAR |
| 2025-08-06 | IMNN | Grant (A) | +3,318 | $30.5K | EDGAR |
| 2025-05-22 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2025-03-18 | IMNN | Grant (A) | — | $0 | EDGAR |
| 2025-01-30 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2024-09-10 | IMNN | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.